Mutations in mprF have been shown to result in reduced susceptibility to daptomycin and other cationic antibacterials. An mprF antisense-inducible plasmid was constructed and used to demonstrate that depletion of mprF can reestablish susceptibility to daptomycin. Inducing antisense to mprF also resulted in increased susceptibility to vancomycin and gentamicin but, paradoxically, decreased susceptibility to oxacillin. These results suggest that mprF mutations that reduce susceptibility to cationic antibacterials result in a gain-of-function phenotype.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019644 | PMC |
| http://dx.doi.org/10.1128/AAC.00429-10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis.
Eur J Clin Microbiol Infect Dis
January 2025
Neonatal Department of Longyan Division, Tianjin Children's Hospital, Tianjin University Children's Hospital, Tianjin, China.
Objectives: Neonatal sepsis is one of the causes of neonatal mortality and bacterial resistance to antibiotics is one of the challenges facing NICU. The aim of this study was to provide a basis for empirical antibiotic selection by comprehensively searching Chinese and non-Chinese databases for studies related to neonatal sepsis pathogenesis conducted in China and synthesizing all the results of the studies conducted in hospitals in China during the period under study METHODS: In this study, we conducted extensive searches of Pubmed, Web of Science, Cochrane, China Biology Medicine disc (SinoMed), China National Knowledge Infrastructure (CNKI) and Wanfang Data. We screened studies published from 2014 to 2023 that were conducted in hospitals in mainland China and involved bacterial blood cultures and susceptibility tests in neonates with neonatal sepsis and extracted the data, which were summarized using Stata 18.
View Article and Find Full Text PDFAssessment of biofilm formation, antibiotic resistance patterns, and the prevalence of adhesion-related genes in clinical isolates.
Heliyon
January 2025
Department of Basic Medical Sciences, Faculty of Medicine, Abadan University of Medical Sciences, Abadan, Iran.
Background: This study aimed to evaluate the biofilm formation abilities of clinical strains, assess their antibiotic susceptibility patterns, and identify the prevalence of adhesion-associated genes.
Methodology: In this study, a total of 60 strains were collected from urine, pus, wounds, blood, body fluid, and sputum in health centers affiliated with Abadan University of Medical Sciences, Iran. Strains were identified via microbiological methods and polymerase chain reaction (PCR) to target the gene.
Combination therapy versus monotherapy: retrospective analysis of antibiotic treatment of enterococcal endocarditis.
BMC Infect Dis
January 2025
Medical Microbiology, Leeds Teaching Hospitals Trust, Leeds, UK.
Background: Guidelines suggest treating fully penicillin-susceptible Enterococcus faecalis strains causing infective endocarditis with amoxicillin combined with gentamicin or ceftriaxone, but clinical evidence to support this practice is limited and monotherapy cohorts were excluded from studies. We describe antibiotic treatment, complications, and outcomes in patients with Enterococcus faecalis infective endocarditis, specifically comparing monotherapy versus combination therapy.
Methods: Retrospective analysis of prospectively collected cohort of patients with definite or possible infective endocarditis from 2 English centres between 2006 and 2021.
antimicrobial susceptibility of clinical isolates from adult and paediatric patients in Jordan: Antimicrobial Testing Leadership and Surveillance (ATLAS) 2010-2021.
Front Antibiot
August 2024
The Medical School, University of Jordan, Amman, Jordan.
Objectives: To evaluate the antimicrobial susceptibilities of Gram-positive and Gram-negative isolates from patients in Jordan between 2010 and 2021, through the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme.
Methods: Medical centres in Jordan collected bacterial isolates from hospitalised patients with defined infection sources between 2010 and 2021 (no isolates collected in 2014). Antimicrobial susceptibility was interpreted using CLSI standards.
Ceftobiprole activity against multidrug-resistant clinical isolates collected in the United States from 2016 through 2022.
Antimicrob Agents Chemother
January 2025
JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant (MRSA) and multidrug-resistant (MDR) clinical isolates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!